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Public concern on mental health has noticeably increased given the high prevalence of
neuropsychiatric disorders. Cognition and emotionality are the most affected functions
in neuropsychiatric disorders, i.e., anxiety disorders, depression, and schizophrenia. In
this review, most relevant literature on the role of the endocannabinoid (eCB) system
in neuropsychiatric disorders will be presented. Evidence from clinical and animal stud-
ies is provided for the participation of CB1 and CB2 receptors (CB1R and CB2R) in the
above mentioned neuropsychiatric disorders. CBRs are crucial in some of the emotional
and cognitive impairments reported, although more research is required to understand the
speciﬁc role of the eCB system in neuropsychiatric disorders. Cannabidiol (CBD), the main
non-psychotropic component of the Cannabis sativa plant, has shown therapeutic potential
in several neuropsychiatric disorders. Although further studies are needed, recent studies
indicate that CBD therapeutic effects may partially depend on facilitation of eCB-mediated
neurotransmission. Last but not least, this review includes recent ﬁndings on the role of the
eCB system in eating disorders. A deregulation of the eCB system has been proposed to
be in the bases of several neuropsychiatric disorders, including eating disorders. Cannabis
consumption has been related to the appearance of psychotic symptoms and schizophre-
nia. In contrast, the pharmacological manipulation of this eCB system has been proposed
as a potential strategy for the treatment of anxiety disorders, depression, and anorexia ner-
vosa. In conclusion, the eCB system plays a critical role in psychiatry; however, detrimental
consequences of manipulating this endogenous system cannot be underestimated over
the potential and promising perspectives of its therapeutic manipulation.
Keywords: cannabinoid receptor, cannabidiol, cognition, emotion, anxiety, depression, schizophrenia, eating
disorders
Psychiatric disorders severely compromise the well-being of those
affected causing serious psychological distress in the general pop-
ulation. These disorders have a relatively high prevalence [Kessler
et al., 2005; Substance Abuse and Mental Health Services Admin-
istration, SAMHSA (2006)], can have an early onset (i.e., schizo-
phrenia in young adulthood) or a relapsing-remitting course (as in
mood and anxiety disorders), and frequently have disabling symp-
toms. Cognition and emotion regulation are the most affected
functions in neuropsychiatric disorders. In fact, such functions
have been reported to be critically impaired in patients suffer-
ing from anxiety disorders, schizophrenia, and major depression
(Hyman, 2008; Dere et al., 2010).
Anxiety is an adaptive component of the acute stress response
under circumstances that threaten the integrity of the individ-
ual, and thus can be regarded as a “normal” emotion. However,
if anxiety is disproportional in intensity or chronicity, or is
not associated with any actual risk, it constitutes a maladaptive
response or even a neuropsychiatric disorder. Indeed, anxiety dis-
orders are marked by excessive fear (and avoidance), often in
response to speciﬁc objects or situations and in the absence of true
danger. Anxiety disorders, such as panic disorder, social and spe-
ciﬁcphobia,generalized anxiety disorder andpost-traumatic stress
disorder (PTSD) are highly prevalent and strongly disabling class
of neuropsychiatric disorders (Bekker and van Mens-Verhulst,
2007; Shin and Liberzon, 2010). Depression is characterized by
abnormal representation and regulation of affect,mood and emo-
tion. Anhedonia, that is, decreased levels of emotional activation
after presentation of rewarding stimuli is generally considered as a
core symptom of depressive patients (Davidson et al., 2002; Levens
and Gotlib, 2009). Cognitive impairments are frequently observed
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in patients with anxiety disorders and depression. Although mild
anxiety seems to be associated with better cognitive performance,
severe anxiety symptoms are negatively associated with cognitive
functioning (Bierman et al., 2005; Gualtieri and Morgan, 2008).
Moreparticularly,PTSD, that develops after prolonged inescapable
stress experience of exceptional severity (Rubin et al., 2008), has
been associated with a number of cognitive impairments, includ-
ing basic deﬁcits in attention, concentration, and memory (Isaac
et al., 2006). In contrast,depressive symptoms are always negatively
associated with cognitive performance. Actually, low episodic
memory performance has been proposed as a premorbid marker
of depression (Airaksinen et al., 2007). Finally, schizophrenia is
characterized by profound disruption in cognition and emotion,
affecting the most fundamental human attributes. A wide diver-
sity of symptoms is described in schizophrenic patients including
hallucinations and delusions, together with remarkable cognitive
deﬁcits that critically inﬂuence the course of the disorder (Barch,
2005).
Cannabis is one of the illicit drugs more frequently abused
in the western societies. A great variety of chemical compounds
are present in the plan of Cannabis sativa, mainly delta-9-
tetrahydrocannabinol (THC), responsible of the addictive and
psychoactive properties of cannabis, and cannabidiol (CBD).
Cannabis, as a drug of abuse, induces changes in the central ner-
vous system (CNS) that may lead to dependence. Indeed, the
development of a dependence syndrome is among the most prob-
able adverse effects of cannabis consumption (Budney et al., 2004;
Fattore et al., 2008). Cannabis consumption induces euphoria, and
is frequently accompanied by decreases in anxiety, although acute
aversive emotional reactions to cannabis have also been reported
(consult Crippa et al., 2009 for review). Notable cognitive impair-
ments have been observed following marijuana intake in humans,
and a contribution neurochemical processes occurring in both
prefrontal cortex and hippocampus have been proposed (Egerton
et al., 2006; Cohen et al., 2008). Therefore, public concern is grow-
ing in relation to the adverse effects of regular use on adolescent
psychosocial development and mental health (Jager and Ramsey,
2008; Hall and Degenhardt, 2009). There is increasing evidence
indicating a close relationship between cannabis consumption
and an increased risk for depression, anxiety disorders, psychotic
symptoms, or even schizophrenia (Degenhardt et al., 2003; Man-
zanares et al., 2004; Sundram, 2006; Di Forti et al., 2007; Leweke
and Koethe, 2008)).
Cannabis derivatives, also known as phytocannabinoids, inﬂu-
ence the CNS through activation of the endocannabinoid (eCB)
system, mainly composed by the endogenous ligands (endo-
cannabinoids, eCBs) and their speciﬁc membrane receptors,
together with the enzymatic machinery in charge of eCB synthesis
and inactivation (Andre and Gonthier, 2010; Maccarrone et al.,
2010). Endocannabinoids have been shown to modulate neuro-
transmission,mainly acting as retrograde transmitters (Marsicano
and Lutz, 2006), and have been involved in a plethora of phys-
iological functions. Data from human and animal studies have
consistently demonstrated that the eCB system is pivotal for emo-
tional homeostasis and cognitive function (Viveros et al., 2007;
Moreira and Lutz, 2008; Solowij and Battisti, 2008; Marco and
Viveros, 2009). In turn, deregulation of the eCB system has been
associated with psychopathological conditions that compromise
emotional and cognitive function, such as anxiety-related disor-
ders, depression, and schizophrenia. Herein, we will review the
latest breakthroughs on the role played by the eCB system in
neuropsychiatric disorders, focusing in emotional, and cognitive
impairments that critically affect individuals’ well-being.
A BRIEF UPDATE ON THE ENDOCANNABINOID (eCB)
SYSTEM
The eCB system system modulates the neurotransmission at
inhibitory and excitatory synapses in brain regions relevant to the
regulation of pain, emotion, motivation, and cognition (Viveros
et al., 2005; Wotjak, 2005; Moreira and Lutz, 2008; Guindon and
Hohmann, 2009; Finn, 2010; Moreira and Wotjak, 2010). In the
last decades, investigation of the eCB system has considerably
increased and our understanding of this system has achieved
remarkable aims (seeAndre andGonthier, 2010;Maccarrone et al.,
2010 for an updated review). Endocannabinoids, the endogenous
ligands, are polyunsaturated fatty acid derivatives that bind to
cannabinoid receptors. Two types of cannabinoid receptors have
been characterized to date, CB1 (Herkenham et al., 1991) and
CB2 receptors (Munro et al., 1993) both metabotropic recep-
tors coupled to Gαi/o proteins. CB1Rs are expressed ubiquitously
throughout the brain; they are found at highest concentrations
in the hippocampus, neocortex, basal ganglia, and cerebellum;
while a moderate presence is observed in the basolateral amygdala,
hypothalamus, and midbrain (Herkenham et al., 1991; Mailleux
andVanderhaeghen, 1992; Glass et al., 1997). Apart from neurons,
CB1Rs have also been described in non-neuronal cells such as
astrocytes (Bouaboula et al., 1995; Sanchez et al., 1998), microglia
(Waksman et al., 1999; Walter et al., 2003), and oligodendrocytes
(Molina-Holgado et al., 2002; for review consult Mackie, 2005).
In contrast, discrepant opinions exist regarding the pattern of
expression of CB2Rs. Initially, CB2R was identiﬁed at high lev-
els in peripheral immune tissues, as rat spleen and immune cells
in humans (Munro et al., 1993; Galiegue et al., 1995), in a lower
extent, in the muscle, liver, intestine, and testis (Liu et al., 2009), as
well as in the adipose tissue (Roche et al., 2006). Additionally,
CB2R was also found in the brain under pathological condi-
tions, i.e., in tumors (Joosten et al., 2002), glioma (Guzman et al.,
2001), neuropathic pain (Ibrahim et al., 2003), senile plaques in
Alzheimer’s disease (Ehrhart et al., 2005), arteriosclerotic plaques
(Steffens et al., 2005), while no CB2R expression was found in
the brain under normal physiological conditions (Chakrabarti
et al., 1995; Derocq et al., 1995; Schatz et al., 1997; Grifﬁn et al.,
1999; Carlisle et al., 2002). However, more recently CB2Rs have
been identiﬁed in cerebellum and brainstem (Van Sickle et al.,
2005). Indeed, further studies have now described the presence
of CB2Rs, both gene and protein expression, in different brain
regions under normal physiological conditions, including cerebral
cortex, striatum, hippocampus, amygdala, periaqueductal gray
(PAG), and several hypothalamic nuclei (Gong et al., 2006; Onaivi,
2006; García-Gutiérrez et al., 2010). Although CB1Rs and CB2Rs
are well-known and characterized, numerous pharmacological
studies have suggested the existence of additional cannabinoid
receptors. In this regard, eCB ligands have been reported to bind
to the transient receptor potential vanilloid type 1 (TRPV1) ion
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channel (Starowicz et al., 2007), and twoGprotein-coupled recep-
tors, GPR55 and GPR119, have been proposed as novel potential
cannabinoid receptors (Baker et al., 2006). Moreover, increasing
evidence now suggests that eCBs are also natural activators of
the peroxisome proliferator-activated receptor (PPAR) family of
nuclear receptors (O’Sullivan and Kendall, 2010).
Endocannabinoids, due to their lipophilic nature, are synthe-
sized and released “on demand” by the cleavage of membrane
phospholipid precursors in response to diverse physiological and
pathological stimuli. The two most widely studied eCBs are N -
arachidonoyl-ethanolamide (AEA), also called anandamide, and
2-arachidonoylglycerol (2-AG). The biological actions of these
polyunsaturated lipids are controlled by key agents responsible for
their synthesis, transport, and degradation. eCBs can passively dif-
fuse through lipid membranes, but a high afﬁnity transporter, not
yet identiﬁed, seems to accelerate this process. A fatty acid amide
hydrolase (FAAH) is the main AEA hydrolase, whereas 2-AG inac-
tivation is mainly afforded by the enzyme monoacylglycerol lipase
(MGL), and by novel 2-AG-hydrolyzing lipases recently identiﬁed
(consult Ahn et al., 2008; Andre and Gonthier, 2010; Maccarrone
et al., 2010; Pamplona and Takahashi, 2011; Ueda et al., 2011; for
more detailed information and/or an updated review).
INVOLVEMENT OF CB1Rs IN NEUROPSYCHIATRIC
DISORDERS
CB1Rs IN ANXIETY DISORDERS
There is substantial evidence from both human and animal stud-
ies for a role of the eCB system in the control of emotional states.
CB1Rs, as mentioned above (A Brief Update on the Endocannabi-
noid (eCB) System), is widely distributed in brain areas asso-
ciated with emotional regulation and stress responsiveness such
as prefrontal cortex, hippocampus, amygdala, and hypothalamus
(Mackie, 2005), thus a role for eCB signaling in anxiety-related dis-
orders might be suggested. Genetic and pharmacological blockade
of CB1Rs further support a role for the eCB system in emotional
homeostasis, and thus in anxiety-related disorders. Mutant mice
lacking CB1Rs (CB1R knock-out mice, CB1KO) display increased
anxiety levels compared to control animals (wild-type) in a variety
of behavioral paradigms, i.e., the light–dark box, the elevated plus-
maze test, and the social interaction test, aswell as increased aggres-
siveness as measured in the resident–intruder test (Haller et al.,
2002; Martin et al., 2002b; Urigüen et al., 2004; but see also Mar-
sicano et al., 2002; Haller et al., 2004). Notwithstanding, baseline
trait levels of emotionality critically affect animals’ performance
in theses tests, and it is in turn notably inﬂuenced by both genetic
strain and environmental testing conditions (Clement et al., 2002;
Yilmazer-Hanke, 2008). In this regard, mutant CB1R mice exclu-
sively exhibited an anxious phenotype under aversive conditions,
i.e., high illumination and ﬁrst exposure in the elevated plus-maze
and the social interaction test (Haller et al., 2002, 2004; Marsicano
et al., 2002;Martin et al., 2002a;Urigüen et al., 2004). Similarly, sys-
temic administration of rimonabant (SR141716A), a cannabinoid
antagonist, induces an anxiogenic proﬁle in rats, i.e., elevated plus-
maze and defensive withdrawal test (Navarro et al., 1997; Arevalo
et al., 2001) in particular if the animals are tested under highly
aversive conditions, i.e., brightly lit environments (Haller et al.,
2004), although contradictory results have been obtained in mice,
i.e., elevated plus-maze (Akinshola et al., 1999; Haller et al., 2002;
Rodgers et al., 2003). It is worth noting that clinical data resemble
rat literature, and in humans rimonabant has been associated with
increased anxiety and depressed mood (Doggrell, 2008; Rosen-
stock et al., 2008; Scheen, 2008; Van Gaal et al., 2008). Indeed,
these adverse psychiatric effects of rimonabant led to the with-
drawal of this anti-obesity drug from the European market1 (Doc.
Ref. EMEA/CHMP/537777/2008). In addition, CB1KO seem not
to respond to the anxiolytic actions of benzodiazepines (Urigüen
et al., 2004) and further studies demonstrated that CB1R is criti-
cally involved in the control of GABAergic neurotransmission, and
so in the anxiolytic actions of benzodiazepines (García-Gutiérrez
and Manzanares, 2010; Urigüen et al., 2011). Given that benzo-
diazepines are one of the most prescribed anxiolytic drugs, the
participation of CB1R in their pharmacological action addition-
ally supports the eCB system as a fundamental piece in anxiety
disorders (see also Viveros et al., 2005; Wotjak, 2005; Marco and
Viveros, 2009; Finn, 2010; Moreira and Wotjak, 2010 for review).
The role of CB1R in learning and memory is well documented
(for review, Wotjak, 2005; Lutz, 2007). CB1R has been speciﬁcally
involved in the facilitationof behavioral adaptation after the acqui-
sition of aversive memories. Marsicano et al. (2002) demonstrated
that the eCB system has a central function in extinction of aversive
memories. Genetic disruption of CB1Rs strongly impaired short-
term and long-term extinction in auditory fear-conditioning tests,
in the absence of changes in memory acquisition and consolida-
tion processes (Marsicano et al., 2002). Interestingly, eCBs seem
to be speciﬁcally involved in extinction of aversive memories since
extinction of appetitive memories were not affected in CB1KO
mice (Holter et al., 2005). Similarly, the pharmacological block-
ade of CB1Rs led to a signiﬁcant impairment in extinction, when
rimonabant was administered prior to extinction training in the
fear-potentiated startle test (Chhatwal et al., 2005). Recent evi-
dence suggests that eCBs may primarily affect habituation-like
processing, thought to be more related to acute fear relief (Kam-
prath et al., 2006). In this context, it has been postulated that
only if a certain threshold of averseness is exceeded by a stimu-
lus and/or test situation is the eCB system activated to exert fear
alleviating effects (Kamprath et al., 2009). Consequently, Moreira
and Wotjak (2010) hypothesized that the eCB system may have
a prevailing protective role to prevent exaggerated fear responses.
If this hypothesis is conﬁrmed, then the eCB system may under-
lie the aberrant memory processing and impaired adaptation to
changed environmental conditions that has been described in sev-
eral human neuropsychiatric disorders, such as PTSD (Isaac et al.,
2006), and new therapeutic opportunities could be offered for the
management of PTSD. In fact, a clinical trial (phase IV) on the
efﬁcacy of THC treatment for the management of PTSD is going
on. Adult subjects of both genders are being currently recruited
and ﬁrst results will be soon available2.
In humans, cannabis is mainly consumed due to its eupho-
riant properties, which are usually accompanied by decreases in
anxiety. However, dysphoric reactions, feelings of anxiety, panic,
1www.emea.europa.eu
2http://ClinicalTrials.gov/show/NCT00965809
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paranoia, and psychosis are also frequently reported (see Crippa
et al., 2009 for review). Similarly, in rodents a bidirectional pro-
ﬁle regarding anxiety-like responses has been reported with low
doses of cannabinoid compounds exerting anxiolytic-like effects
while the opposite is observed following the administration of
high doses (consult for review, Viveros et al., 2005; Moreira
and Lutz, 2008). Despite basal emotional state as well as con-
textual testing conditions are critical in this respect, putative
neural mechanisms underlying this biphasic proﬁle have been
thoroughly investigated. Anxiolytic- and anxiogenic-like effects
of cannabinoid agonists appear to be mediated through the same
neurotransmitter systems although by activating different recep-
tors. The endogenous opioid system is involved in the regulation
of cannabinoid-induced anxiety-like responses; pharmacological
studies indicate that anxiolytic-like responses are mediated by
μ- and δ-opioid receptors (Berrendero and Maldonado, 2002)
while κ-opioid receptors might be involved in the anxiogenic-like
responses (Marin et al., 2003).The serotonergic system, particu-
larly 5-HT1A receptors (5-HT1ARs), participate in the anxiety-
related effects of cannabinoid compounds although controversial
results have been reported (Marco et al., 2004; Braida et al., 2007).
GABAergic and glutamatergic neurotransmissions have also been
involved in the anxiety-like responses to cannabinoid compounds.
CB1Rs have been localized on both glutamatergic (Domenici et al.,
2006; Kawamura et al., 2006; Monory et al., 2006) and GABAer-
gic (Katona et al., 1999, 2001) neurons but such receptors may
differ in their sensitivity to cannabinoid compounds. Actually,
differences in the cannabinoid sensitivity of glutamatergic and
GABAergic neurotransmission between mice and rats was sug-
gested to underlie the differences in cannabinoid-induced anxiety-
related responses previously described (Haller et al., 2007). More
recently, the contribution of GABAergic and glutamatergic neu-
rotransmission in the biphasic emotional effects of cannabinoids
has been analyzed by using KO mice speciﬁcally lacking CB1R
in GABAergic neurons (GABA-CB1KO) or glutamatergic fore-
brain neurons (Glu-CB1-KO). The presence of CB1Rs on the
glutamatergic terminals may be considered as a requirement for
the anxiolytic-like responses elicited following the administration
of low doses of a cannabinoid agonist. In contrast, CB1Rs on
GABAergic terminals seem to be involved in the anxiogenic-like
effects associated to high doses of cannabinoid compounds (Lutz
et al., 2010). Taken together, cannabinoid agonists, depending
upon their chemical structure and dosage, may act on a diversity
of cannabinoid and non-cannabinoid receptors [see above,A Brief
Update on the Endocannabinoid (eCB) System] present in distinct
neuroanatomical regions and differing in their binding properties.
Despite the great efforts devoted to understand the biphasic proﬁle
of cannabinoid-induced effects, not exclusive of emotional-related
responses, a consensus on the underlying mechanisms has not yet
been reached.
Our knowledge on the role of the eCB system in emotion and
anxiety disorders has notably increased in the last decade. Data
presently available provide evidence for an intrinsic eCB tone
that may control emotional homeostasis, mainly acting through
CB1R activation. Equilibrium in eCB signaling is pivotal not
only to maintain adequate baseline anxiety levels, but also to
promote recovery and/or adaptation to stressful and aversive
situations. Disequilibrium or malfunctioning of the eCB system
might contribute to the etiology of anxiety-related disorders (Sun-
dram, 2006; Marco and Viveros, 2009; Finn, 2010; Parolaro et al.,
2010), whereas the pharmacological enhancement of eCB activa-
tion may provide a promising therapeutic tool for the manage-
ment of such disorders (Pacher et al., 2006; Piomelli et al., 2006).
Given the successful results accomplished in animal studies, great
expectations exist for the future clinical exploitation of this system.
CB1Rs IN DEPRESSION
Several hypotheses for the neurobiological basis of depression have
been formulated (Nestler et al., 2002), and, in the last years, a dereg-
ulation of the eCB system has been proposed (for review consult
Vinod and Hungund, 2006; Parolaro et al., 2010; Gorzalka and
Hill, 2011). Evidence for a relationship between the eCB system
and human depression has arisen. Clinical populations diagnosed
with depression are found to have reduced levels of circulating
eCBs (Hill et al., 2009) and anup-regulation of CB1Rwas observed
in the prefrontal cortex of subjectswithmajor depressionwhodied
by suicide (Hungund et al., 2004). Furthermore, a genetic risk fac-
tor for depression in Parkinson’s diseasewas found to be associated
with polymorphisms of human gene for CB1R (CNR1), mapped
to chromosome 6q14–15 (Barrero et al., 2005). More recent stud-
ies have conﬁrmed that polymorphisms in the CNR1 gene are a
risk factor for depression, and have suggested that the CNR1 gene
inﬂuences vulnerability to psychosocial adversity to later develop
depressive symptoms (Juhasz et al., 2009).
Evidence from animal models further support the participa-
tion of CB1R in depression. Genetic deletion of CB1R has been
reported to induce a behavioral state analogous to depression
in experimental animals. CB1KO mice became anhedonic before
than wild-type mice when exposed to chronic mild stress (CMS),
so lack of CB1R may render animals more vulnerable to the anhe-
donic effect of chronic stress (Martin et al., 2002a). CB1KO mice
have been reported to exhibit a decreased sensitivity to rewarding
stimuli (Sanchis-Segura et al., 2004) and a depressive-like phe-
notype in both the forced–swim test (FST; Steiner et al., 2008)
and the test suspension test (TST; Aso et al., 2008). A deﬁcit in
extinction of aversive memories has also been reported (Marsi-
cano et al., 2002). Impairments in working memory, measured
as spontaneous alternation, have been described in CB1KO mice
(Ledent et al., 1999), although performance in other cognitive
tasks, i.e., object recognition and active avoidance, was not found
to be affected (Reibaud et al., 1999; Maccarrone et al., 2002;
Martin et al., 2002a). In addition, anomalies in the hypothalamus–
pituitary–adrenal (HPA) axis have been described in CB1KOmice.
In particular, an hyperactivity of the HPA axis as suggested by the
higher corticosterone levels registered in CB1KO mice after expo-
sure to stress compared to control wild-type animals (Urigüen
et al., 2004). Taken together, genetic depletion of theCB1R resulted
in a “depressive-like” phenotype at the preclinical level; CB1KO
mice displayed an anhedonic state, emotional changes, cognitive
deﬁcits, an increased HPA axis activity as well as impairments
in stress adaptation (reviewed by Vinod and Hungund, 2006;
Parolaro et al., 2010; Gorzalka and Hill, 2011). Brain derived neu-
rotrophic factor (BDNF) is considered a biochemical marker of
depression. Actually, depression has been associated to a reduced
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expression of BDNF in the hippocampus (Yu and Chen, 2010).
Accordingly, decreased BDNF levels have been observed in the hip-
pocampus of CB1KO mice (Aso et al., 2008; Steiner et al., 2008).
In a more recent study, gene expression of CB1KO versus control
wild-typemice has been analyzed by usingmicroarrays technology
(Aso et al., 2011). The study revealed an altered gene expression
pattern in CB1KO mice (at basal conditions) that may contribute
to the depressive-like phenotype and to the increased reactivity
to stress previously described in these mutant animals (Aso et al.,
2011). A comparative study following repeated exposure to stress
was also performed, and most differences in stress reactivity were
observed in the raphe nucleus, a brain region closely related to
depression (Aso et al., 2011).
Apart from evidences from the genetic and pharmacological
blockade of CB1R, changes in receptor expression have also been
described in diverse animal models of depression (Table 1). A
consistent increase of CB1R expression in the prefrontal cor-
tex has been reported in different animal models of depression,
i.e., CMS (Bortolato et al., 2007), chronic unpredictable stress
(Hill et al., 2008), and bilateral olfactory bulbectomy (Rodriguez-
Gaztelumendi et al., 2009). Noticeably, a similar effect was found
for cortical CB1R expression in a population of depressed suicides
(Hungund et al., 2004). In contrast, decreases in CB1R expression
have been reported in hippocampus (Hill et al., 2005, 2008; Reich
et al., 2009), hypothalamus, ventral striatum (nucleus accumbens;
Hill et al., 2008), and midbrain (Bortolato et al., 2007). However,
discrepancies regarding changes in CB1R expression in animal
models of depression have been found, andmayprobably be due to
differences in the animal model employed and/or in the technique
used. Sex differences have been reported for several aspects of
pathologies, however, male and female animals are hardly con-
sidered in preclinical studies. In the CMS model of depression a
down-regulation of hippocampal CB1R has been observed among
adult male animals (Hill et al., 2005, 2008; Reich et al., 2009),
whereas a CB1R up-regulation was found exclusively in the dorsal
hippocampus of females (Reich et al., 2009). In accordance with
these ﬁndings, sex differences in the eCB systemmight be hypothe-
sized, at least in relation to stress-responding circuitries. However,
more research is still needed to better understand the behavioral
implications of the regional and sexual speciﬁc changes in brain
CB1R expression.
As for anxiety disorders, a dysfunction of the eCB system has
been proposed to be in the bases of depression (Vinod and Hun-
gund,2006;Parolaro et al., 2010;Gorzalka andHill,2011). Enhanc-
ing the levels of eCBs by inhibiting their deactivation has become
a promising antidepressant strategy (Pacher et al., 2006; Bambico
and Gobbi, 2008). In contrast, inactivation of CB1Rs can have
detrimental consequences provoking depressive-like symptoms.
In fact, rimonabant adverse effects included not only increased
anxiety, but also depression and suicidal ideations (Doggrell, 2008;
Rosenstock et al., 2008; Scheen, 2008;Van Gaal et al., 2008). In this
line, an association between depression and prolonged cannabis
consumption and its withdrawal have also been reported (Degen-
hardt et al., 2003). Despite appealing, existing literature suggests
caution in the pharmacological exploitation of the eCB system.
Indeed, further investigation is necessary to understand the clini-
cal limits of such manipulation that may differ among sexes, age,
and individuals.
Table 1 | Changes in CB1R expression in depressed patients and animal models of depression.
Model/diagnosis Species Brain region CB1R expression References
Depressed suicide victims Human Dorsolateral prefrontal cortex ↑ Hungund et al. (2004)1
CMS Rat, Wistar Prefrontal cortex ↑ Bortolato et al. (2007)3
Hippocampus –
Midbrain ↓
Rat, Sprague-Dawley Hippocampus – males ↓ Reich et al. (2009)1
Hippocampus (dorsal) – females ↑
CUS Rat, Long-Evans Hippocampus ↓ Hill et al. (2005)1
Limbic forebrain –
Rat, Long-Evans Prefrontal cortex ↑ Hill et al. (2008)2
Hippocampus ↓
Hypothalamus ↓
Amygdala –
Midbrain –
Ventral striatum ↓
OBX Rat, Sprague-Dawley Prefrontal cortex ↑ Rodriguez-Gaztelumendi et al. (2009)2
Caudate–putamen –
Hippocampus –
Amygdala ↑
Dorsal raphe nucleus –
Animal models of depression: CMS, chronic mild stress; CUS, chronic unpredictable stress; OBX, bilateral olfactory bulbectomy. Symbols, ↑ increased, – not modiﬁed,
or ↓ decreased receptor expression. Receptor protein expression was evaluated by Western blotting1, or binding assays2; and gene expression by real-time PCR3.
Modiﬁed from Parolaro et al. (2010) and extended.
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CB1Rs IN SCHIZOPHRENIA
The association between cannabis use and psychosis has long
been recognized (see for review, D’Souza et al., 2009), and recent
advances in the neurobiology of cannabinoids have renewed inter-
est in the association between cannabis and schizophrenia (see
Muller-Vahl and Emrich, 2008; Fernandez-Espejo et al., 2009;
Parolaro et al., 2010 for review). There are several lines of evidence
that support an association between an altered eCB system and the
pathogenesis of schizophrenia. In clinical studies, up-regulation
of CB1R has been described in cortical brain regions such as the
dorsolateral prefrontal cortex (Dean et al., 2001) and in cingulate
cortex (Zavitsanou et al., 2004;Newell et al., 2006) of schizophrenic
patients. However, investigation in post mortem schizophrenic
brains have yielded contrasting results, and a both no changes
or even decreases in CB1R expression have also been described.
No changes in the superior temporal gyrus (Deng et al., 2007),
and the anterior cingulate cortex (Koethe et al., 2007) have been
found as well as decreases in CB1R expression in the prefrontal
cortex (Eggan et al., 2008). Unfortunately, most of the studies did
not consider the pharmacological treatment given to patients, a
confounding factor that may have altered the results achieved.
Indeed, antipsychotics have been reported to decrease prefrontal
cortex CB1R expression in schizophrenic patients in the absence
of changes in drug-free schizophrenics (Uriguen et al., 2009).
In addition, genetic studies have indicated that variants within
the CNR1 gene are directly associated with schizophrenia. Indi-
viduals with a 9-repeat allele of an AAT-repeat polymorphism
of the CNR1 gene showed a 2.3-fold higher susceptibility to
the hebephrenic form of schizophrenia in a Japanese population
(Ujike and Morita, 2004), that was further conﬁrmed in a popu-
lation of the Central Valley of Costa Rica (Chavarria-Siles et al.,
2008). However, such an association was no longer present if more
general types of schizophrenia were considered. In addition, the
presence of a polymorphism (G allele) of CNR1 has been associ-
ated with a better therapeutic effect of antipsychotics (Hamdani
et al., 2008). Despite numerous data that support this association,
negative data have also been found (Tsai et al., 2000; Seifert et al.,
2007); therefore, the debate about the existence of a real relation-
ship between CNR1 mutations and schizophrenia is still open and
deserves further investigations.
Contribution of CB1Rs to schizophrenia has also been investi-
gated in animal models that mimic some of the symptoms of the
disease (Table 2). The schizophrenic-like effects induced by the
administration of phencyclidine (PCP), a N -methyl-d-aspartate
(NMDA) antagonist, in wild-type mice (e.g., increased locomo-
tion, stereotyped behaviors, and decreased social interactions)
were not observed in CB1KO mice. In contrast, PCP adminis-
tration in CB1KO mice decreased locomotion, notably enhanced
ataxia and stereotypy but induced no changes in social interaction.
Since genetic CB1R blockade dramatically alters the behavioral
consequences of PCP, this receptor may play a critical role in
schizophrenia, although a differential participation in the negative
(e.g., social disruption) and positive symptoms (e.g., stereotypy)
of schizophrenia was hypothesized (Haller et al., 2005). Repeated
PCP injections have been extensively used to induce enduring cog-
nitive deﬁcits with particular relevance to schizophrenia (consult
Amitai et al., 2007; Grayson et al., 2007 as examples), and the
participation of the eCB system in this PCP model of cognitive
dysfunction have been analyzed (Vigano et al., 2009). Chronic-
intermittent PCP administration induced an enhancement in
CB1R density in the amygdala and in the ventral tegmental area
when compared to the control group. Similarly, CB1R function-
ality was also altered in several brain areas implicated in schiz-
ophrenia; in particular, it was reduced in the prefrontal cortex,
hippocampus, substantia nigra, and cerebellum, and increased in
the globus pallidus. Alterations in endocannabinoid levels mainly
in the prefrontal cortex, i.e., an increase in the levels of 2-AG in
PCP-treated rats, were also found. These ﬁndings allowed authors
to suggest that a maladaptation of the endocannabinoid system
might contribute to the glutamatergic-related cognitive symp-
toms encountered in schizophrenia disorders (Vigano et al., 2009).
Furthermore, chronic THC administration worsened cognitive
performance in this animal model (Vigano et al., 2009), providing
evidence for the hypothesis that cannabis consumption may be
a risk factor for development or worsening of the schizophrenia
disorder.
Increasing evidence gives support to the fact that schizophrenia
is a subtle disorder of brain development and plasticity (Lewis and
Levitt, 2002; Tyrka et al., 2008), thus reinforcing the neurodevel-
opment hypothesis of schizophrenia. Brain developmental abnor-
malities, often related to early traumatic experiences, have been
extensively associated to schizophrenia (Lewis and Levitt, 2002;
Tyrka et al., 2008). Therefore, changes in CB1R expression have
been analyzed in schizophrenia animal models with a base in neu-
rodevelopment, i.e., early maternal deprivation (Ellenbroek and
Riva, 2003; Marco et al., 2009). At adulthood, maternally deprived
animals (24 h at postnatal day 9) show behavioral abnormali-
ties that resemble psychotic-like symptoms (Ellenbroek and Riva,
2003) including notable cognitive impairments (Llorente et al.,
2011; Llorente-Berzal et al., 2011). Notably, a long-lasting decrease
inCB1Rexpressionhas been found inmaternally deprived animals
within the hippocampus. Such a reduction in CB1R expression
was observed in the short-term, at postnatal day 13, in both male
and female rat pups (Suarez et al., 2009), as well as in the long-
term, at adulthood (Llorente-Berzal et al., 2011), thus suggesting a
endurable impact of early maternal deprivation in the eCB system
that may contribute to some of the behavioral anomalies observed
in these animals. Rearing rats in isolation has also been used as
a model for the investigation of schizophrenia (consult Fone and
Porkess, 2008 for review). Following isolation rearing, rats display
social, and cognitive impairments. In particular, hyperlocomotion
and increased aggressiveness have been reported, together with
deﬁcits in memory recognition and a reduce PPI response (Sci-
olino et al., 2010; Zamberletti et al., 2010). In relation to changes
in the eCB system, raising rats in isolation led to a signiﬁcant
decrease in CB1R expression in caudate–putamen and amygdala
(Malone et al., 2008).However, discrepant data have been achieved
in more recent studies using this animal model of schizophrenia.
Increases in CB1R expression has been described in the caudate–
putamen of isolated-reared rats (Sciolino et al., 2010) as well as in
prefrontal cortex, certain thalamic nuclei and the posterior area of
the hypothalamus (Robinson et al., 2010). In contrast, decreases in
receptor expression have been reported in the supraoptic nucleus
of the hypothalamus and in the ventrolateral thalamic nucleus
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Table 2 | Changes in CB1R expression in schizophrenia and animal models of neuropsychiatric disorders.
Model/diagnosis Species Brain region CB1R expression References
Schizophrenia Human, Victorian Institute of Forensic
Medicine, Victoria (Australia)
Dorsolateral prefrontal cortex ↑
Dean et al. (2001)
Caudate–putamen –
Areas within the temporal lobe –
Human, New South Wales Tissue Resource
Centre, University of Sydney (Australia)
Anterior cingulate cortex ↑
Zavitsanou et al. (2004)
Human, New South Wales Tissue Resource
Center, University of Sydney (Australia)
Posterior cingulate cortex ↑
Newell et al. (2006)
Human, NSWTissue Resource Centre
(Australia)
Superior temporal gyrus –
Deng et al. (2007)
Human, Stanley Neuropathology Consortium
Collection, Bethesda, MD (USA)
Anterior cingulate cortex –
Koethe et al. (2007)
Human, mainly died by suicide, Basque
Institute of Legal Medicine, Bilbao (Spain),
Institute of Forensic Medicine, Geneva
(Switzerland)
Dorsolateral prefrontal cortex –
Uriguen et al. (2009)
Human, Allegheny County Medical
Examiner’s Ofﬁce, Pittsburgh, Pennsylvania
Dorsolateral prefrontal cortex ↓
Eggan et al. (2008)
C–PCP Rats, Lister-Hooded Amygdala ↑
Vigano et al. (2009)
Ventral tegmental area ↑
MD Rats, Wistar Hippocampus ↓
Suarez et al. (2009)
Rats, Wistar Hippocampus ↓
Llorente-Berzal et al. (2011)
IR Rats, Sprague-Dawley Caudate–putamen ↓
Malone et al. (2008)
Amygdala ↓
Rats, Sprague-Dawley Diverse brain regions –
Zamberletti et al. (2010)
Rats, Sprague-Dawley Caudate–putamen (rostral) ↑
Sciolino et al. (2010)
Hypothamalus (superoptic
nucleus)
↓
Thalamus nuclei (ventrolateral) ↓
Rats, Sprague-Dawley Prefrontal cortex ↑
Robinson et al. (2010)
Thalamic nuclei ↑
Hypothalamus (posterior area) ↑
Animal models of schizophrenia: C–PCP, chronic and intermittent PCP administration; MD, maternal deprivation (24 h on postnatal day 9); IR, rearing in social isolation.
Symbols, ↑ increased or ↓ decreased receptor expression. In animal models, only changes in affected brain regions are described.
(Sciolino et al., 2010). In another study, in the absence of changes
in CB1R expression, isolated-reared rats presented a consistent
decrease in CB1R functionality in most of the regions analyzed,
i.e., prefrontal cortex, nucleus accumbens, caudate–putamen, hip-
pocampus, and ventral tegmental area (Zamberletti et al., 2010).
Discrepancies may be due to the different techniques employed to
evaluate CB1R density, to differences in the rat strains used, as well
as in the duration of the isolation rearing protocol. Even though,
taken together, these results indicate that the eCB system is altered
in this animal model of schizophrenia, i.e., rearing in social isola-
tion. In spite of the current discrepancies regarding CB1R changes
in animal models of schizophrenia, present ﬁndings point to the
eCB system as a pivotal neuromodulatory pathway that may have
a critical relevance in the psychotic-related behaviors observed in
these animals, i.e., altered emotionality and social and cognitive
deﬁcits. However, further research is needed to better understand
the region-speciﬁc CB1R changes here described, and to estab-
lish a direct correlation between such changes and the behavioral
anomalies reported.
There is now evidence demonstrating an association between
increased rates of cannabis use and new cases of schizophrenia
(see for review,Di Forti et al., 2007; Cohen et al., 2008; Leweke and
Koethe, 2008). Epidemiological studies suggest a high incidence of
schizophrenia within marijuana smokers (Moore et al., 2007) and
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long-term users of cannabis exhibit similar cognitive deﬁcits to
those seen in schizophrenia (Solowij and Michie, 2007). Cannabis
has been considered a risk factor for development or worsening
of the schizophrenia disorder, and evidence indicating that young
people at genetic high risk for schizophrenia are particularly vul-
nerable to mental health problems associated with cannabis use
is now available (Hollis et al., 2008). Moreover, cannabis use has
been associated with a decrease in age of onset of schizophre-
nia, frequently related with a poorer outcome (Sugranyes et al.,
2009). Literature from animal models further support adolescence
as a highly vulnerable age for the consequences of cannabis expo-
sure (Schneider, 2008).Adolescent chronic cannabinoid treatment
leads to long-lasting behavioral deﬁcits. Decreased emotional-
ity (Biscaia et al., 2003; Wegener and Koch, 2009), although no
changes in locomotor activity nor in object recognition mem-
ory have been reported (Schneider et al., 2005). Lasting disrup-
tion of pre-pulse inhibition (Schneider et al., 2005; Wegener and
Koch, 2009) as well as persistent deﬁcits in social recognition
and impaired social interaction have been described following
adolescent cannabinoid administration (Leweke and Schneider,
2011). Such behavioral anomalies were restored by antipsychotic
treatment, further conﬁrming the suitability of chronic pubertal
cannabinoid administration as an animal model for diverse aspect
of schizophrenia (Wegener andKoch, 2009; Leweke and Schneider,
2011). Despite more research is needed, reducing and/or limiting
cannabis consumption in our society, especially among vulnerable
populations (adolescents andpeople at risk for psychopathologies)
might be convenient in order to reduce dependence and mental
health risks in society.
A ROLE FOR CB2Rs IN NEUROPSYCHIATRIC DISORDERS
Despite CB2R was initially claimed as a peripheral cannabinoid
receptor, its presence in CNS is still controversial [see A Brief
Update on the Endocannabinoid (eCB) System]. As previously
mentioned, CB2R has been detected in a diversity of brain regions
including cerebral cortex,hippocampus, amygdala,hypothalamus,
and cerebellum (Van Sickle et al., 2005; Gong et al., 2006; Onaivi,
2006; García-Gutiérrez et al., 2010), thus suggesting a role for
CB2Rs in emotional and cognitive function.
CB2Rs IN MOOD DISORDERS: ANXIETY AND DEPRESSION
Recent results from mice with genetically modiﬁed CB2R sug-
gest that CB2R-signaling is clearly involved in the regulation of
emotional behavior (Table 3). Mice lacking CB2R (CB2R knock-
out mice, CB2KO) presented increased vulnerability to stressful
stimuli in the light–dark box, the elevated plus-maze, and the
TST (Ortega-Alvaro et al., 2011). In contrast, transgenic mice
over-expressing CB2R in the CNS (CB2xP; Racz et al., 2008a,b)
presented a clear endophenotype resistant to stressful stimuli in
the light–dark box and elevated plus-maze tests (Ortega-Alvaro
et al., 2011). These results are not consistent with those reported by
Onaivi et al. (2008b) showing that intracerebroventricular admin-
istration of an antisense oligonucleotide directed against CB2R
mRNA resulted in anxiolytic-like effects in mice. Discrepancies
between these two studies may be due to the fact that (1) the
effects of intracerebroventricular administration of CB2 antisense
oligonucleotide could act on different brain regions thatmay differ
from those where CB2R are over-expressed in CB2xP mice, and
(2) the different genetic background used in both studies (DBA/2,
C57BL/6, BALB/c, and Swiss ICR). Similarly, CB2xP mice exhib-
ited an endophenotype resistant to acute depressogenic-like stim-
uli (novelty-suppressed feeding test, NSFT, and TST) and CMS.
Indeed, 6 weeks after CMS, CB2xP mice presented reduced pas-
sive coping behavior in the TST and did not experience anhedonia
(García-Gutiérrez et al., 2010). The marked behavioral alterations
occurring in CB2xP mice were associated with changes in BDNF,
a well-known biochemical marker of depression (see also section
“CB1RS in depression”). BDNF plays an important role in adult
neurogenesis by modulating survival and plasticity of adult neu-
rons and glia cells (Huang and Reichardt, 2001). As previously
mentioned, depression has been associated to a decrease in hip-
pocampal BDNF expression (Yu andChen, 2010), probably related
to the reported reduction in hippocampal neurogenesis previously
described among patients with mood disorders (Sheline, 2000). In
accordance, a similar decrease in hippocampal BDNF has been
reported in animals exposed to CMS, probably indicating dimin-
ished hippocampal neurogenesis (Manji et al., 2001; Nestler et al.,
2002). Interestingly, CMS failed to produce any modiﬁcation in
BDNFprotein and gene expressions in the hippocampus of CB2xP
mice (García-Gutiérrez et al., 2010). All these data support the
role of CB2R in the normalization of reduced BDNF expression
of mice exposed to CMS and suggests the involvement of CB2R in
the regulation of mood disorders. In line with these ﬁndings, an
association between cannabinoid CB2R polymorphism Q63R has
been detected in Japanese depressed subjects (Onaivi et al., 2008a).
Taken together, these results allow us to hypothesize that the
overexpression of CB2R decreases the vulnerability to depres-
sogenic stimuli. The idea to induce CB2R overexpression by
pharmacological manipulation was carried out by treating chron-
ically wild-type mice with the cannabinoid CB2R antagonist,
AM630. Indeed, 4 weeks of administration with AM630 increased
CB2R gene expression (thus mimicking the phenotype of CB2xP
mice), reversed the CMS-induced reduction of immobility evalu-
ated in the TST, the diminished sucrose solution intake, and the
diminished CB2R and BDNF gene and protein expression in the
hippocampus (García-Gutiérrez et al., 2010). However, previous
studies reported a lack of effects after the administration of AM630
on the intake of sucrose solution in CMS (Onaivi et al., 2008a).
These discrepancies may be due to: (1) individual and species
differences between the strains used and (2) different dosage or
pattern of administration of AM630. Onaivi and colleagues used
doses of 1 or 3mg/kg once a day. In contrast, García-Gutiérrez
et al. (2010) studied the effects of AM630 (1mg/kg) administered
twice a day.
In addition, the behavioral picture of CB2xP mice was par-
alleled with alterations in the HPA axis. Changes in the HPA axis
have been associated with anxiety-related disorders in rodents and
humans (see also previous section). The reduced secretion of HPA
axis hormones was also detected in patients with stress-related
disorders. Indeed, hypocortisolism was observed in patients with
PTSD, fatigue syndrome, ﬁbromyalgia, and other somatoform
disorders (Heim et al., 2000). Restraint stress slightly increased
pro-opiomelanocortin (POMC) gene expression (22%) in the
arcuate nucleus of hypothalamus in CB2xP mice whereas failed to
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Table 3 | Evidences for a role of CB2R in emotional behavior and neuropsychiatric disorders.
Genetic manipulation of CB2Rs
Mutation Species Paradigm Behavioral phenotype References
Lack of CB2R, knock-out
(CB2KO)
Mouse, Swiss ICR OF ↓ Spontaneous motor activity Ortega-Alvaro et al.
(2011)
OF ↑ Sensitivity to the motor stimulant effects
of cocaine
LD, EPM,
TST
↑ Vulnerability to anxiogenic and
depressogenic-like stimuli
SDIA Disrupted short- and long-term memory
consolidation
PPI ↑ PPI response
Overexpression of CB2R
(CB2xP)
Mouse, Swiss ICR TST, NSFT,
CUMS
↓ Vulnerability to depressogenic-like stimuli García-Gutiérrez et al.
(2010)
LD, EPM ↓ Vulnerability to anxiogenic-like stimuli García-Gutiérrez and
Manzanares (2011)
LD Lack of anxiolytic effects of benzodiazepines
(alprazolam)
Pharmacological manipulation of CB2Rs
Drug Species Paradigm Treatment, dose Response References
ACUTETREATMENT
GW405833 (CB2R agonist) Rats, Sprague-Dawley MB 10 and 30mg/kg – Valenzano et al. (2005)
Rotarod 100mg/kg ↓ Anxiety-like
responses and ataxia
JWH015 (CB2R agonist) Mouse, C57BL/6 EPM 1–20mg/kg ↓ Anxiety-like responses Onaivi (2006)
Mouse, C57BL/6 LD 1–20mg/kg ↑ Anxiety-like responses Onaivi et al. (2008b)
JWH133 (CB2R agonist) Mouse, Swiss ICR LD 0.5, 1, and 2mg/kg – García-Gutiérrez et al.
(2011)
SR144528 (CB2R antagonist) Mouse, BALBc LD 1–20mg/kg – Onaivi et al. (2008b)
AM630 (CB2R antagonist) Mouse, Swiss ICR LD 1, 2, or 3mg/kg ↑ Anxiety-like responses García-Gutiérrez et al.
(2011)
CHRONICTREATMENT
JWH133 (CB2R agonist) Mouse, Swiss ICR LD 0.5, 1, or 2mg/kg ↑ Anxiety-like responses García-Gutiérrez et al.
(2011)
EPM 1week (twice a day)
JWH015 (CB2R agonist) Mouse, BALBc AT 20mg/kg Enhanced sucrose
consumption
Onaivi et al. (2008b)
4weeks (once a day)
AM630 (CB2R antagonist) Mouse, BALBc AT 1 and 3mg/kg – Onaivi et al. (2008b)
4weeks (once a day)
Mouse, Swiss ICR CUMS 1, 2, and 3mg/kg Antidepressant-like García-Gutiérrez et al.
(2010)
4weeks (twice a day)
Mouse, Swiss ICR LD 1, 2, and 3mg/kg ↓ Anxiety-like responses García-Gutiérrez et al.
(2011)
EPM 1week (twice a day)
All drugs were administered intraperitoneally (ip).Behavioral paradigms: OF, Open ﬁeld; LD, light–dark box; EPM, elevated plus-maze; TST, tail suspension test; SDIA,
step down inhibitory avoidance; PPI, pre-pulse inhibition of the acoustic startle response; NSFT, novelty-suppressed feeding test; CUMS: chronic unpredictable mild
stress; MB, marble burying test; AT, anhedonia test: sucrose consumption. Symbols, ↑ increased (anxiogenic-like), ↓ decreased (anxiolytic-like), or – no changes in
behaviour.
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produce any modiﬁcation in corticotropin releasing factor (CRF)
gene expression of the paraventricular nucleus (García-Gutiérrez
and Manzanares, 2011). These results suggest that CB2R may be
contributing to the maintenance of the steady state control of
the HPA axis. The fact that the overexpression of CB2R blocked
the effects of stress on CRF gene expression points to the idea
that the mechanism controlling the HPA axis in CB2xP mice
may be acting at the level of synthesis or release of CRF. The
overexpression of CB2R was also accompanied by changes in the
GABAergic system, more particularly by alterations of GABA-A
receptor subunits. Benzodiazepines are anxiolytic drugs often used
in the treatment of certain anxiety or mood related disorders. Ben-
zodiazepines, acting through their binding on the interface of α
and γ subunits of the GABA-A receptor complex are known to
act as anxiolytics promoting the inhibitory actions of the GABA
neurotransmitter in the CNS (Da Settimo et al., 2007). Recent
studies suggested that GABA-A receptors containing α2 and γ2,
enriched in corticolimbic structures mediate the anxiolytic effect
of benzodiazepines (Low et al., 2000). The administration of alpra-
zolam, a well-known anxiolytic benzodiazepine, failed to produce
any effect in CB2xP mice at either of the doses used (45 and
70μg/kg; García-Gutiérrez and Manzanares, 2011). This behav-
ioral scenario was associated to changes in the expression of α2
and γ2 subunits of GABA-A receptors in speciﬁc brain areas.
Increased GABA-A α2 and γ2 subunits receptor gene expression
was found in the amygdala and hippocampus of CB2xP mice
(García-Gutiérrez and Manzanares, 2011). The increased gene
expression of both GABAergic subunits may be related, at least
in part, with the lack of the anxiolytic effect of benzodiazepines
in CB2xP mice. Moreover, these results support the potential
implication of CB2R in the regulation of GABAergic system. In
this respect, recent studies revealed a suppression of GABAergic
inhibitory signaling in the entorhinal cortex–hippocampal slices
following the administration of the cannabinoid CB2R agonist,
JWH133 (50 nM). Interestingly, these effects could be blocked by
prior administration of AM630 (50 nM) supporting the involve-
ment of CB2R in the effects of JWH133 on GABAergic signal-
ing (Morgan et al., 2009). These results further strengthen the
involvement of CB2R in the regulation of GABAergic release from
neuronal terminals.
Pharmacological manipulation of CB2R may alter the response
to anxiogenic or depressogenic-like stimuli (see Table 3 for
details). In rodents, the pharmacologicalmanipulation of CB2Rby
the administrationof agonists or antagonists resulted in controver-
sial reported effects on emotional behavior. Acute administration
of GW405833 (100mg/kg), a CB2R agonist, induced anxiolytic
effects in the marble burying test (Valenzano et al., 2005). Indeed,
an anxiolytic effect in the elevated plus-maze test was reported
after the acute administration of the CB2R agonist, JWH015
(Onaivi, 2006). In contrast, the same group reported anxiogenic
effects of JWH015 in the light–dark box (Onaivi et al., 2006).
The present discrepancies may be due to: (1) the drugs used,
(2) the route of drug administration, (3) the doses used, and (4)
the strain of mice studied. Indeed, the fact that the doses of the
CB2R agonist used resulted in motor alterations may have masked
the interpretation of these behavioral effects. A recent publica-
tion evaluated the effects of acute and chronic administration of
JWH133, a CB2R agonist, and AM630, a CB2R antagonist, on
emotional behavior at doses that did not modify motor activity.
Acute administration of JWH133 failed to produce any modiﬁ-
cation in the response to acute stimuli in the light–dark test. In
contrast, the acute blockade of CB2R by AM630 resulted in anx-
iogenic effects. The fact that the anxiogenic effects of AM630 were
blocked by the previous administration of JWH133 supported the
involvement of CB2R in the acute effects of AM630 on emotional
behavior (García-Gutiérrez et al., 2011). However, chronic block-
ade of CB2R by the antagonist AM630 resulted in anxiolytic effect
associated with increased CB2R gene and reduced CB2R protein
expression in cortex and amygdala. In contrast, chronic activa-
tion of CB2Rs by JWH133 resulted in an opposite behavioral and
molecular alterations. Mice chronically treated with JWH133 pre-
sented an anxiogenic effect associated with reduced CB2R gene
and increased CB2R protein expression in cortex and amygdala.
Indeed, the administration of JWH133 and AM630 are associated
with alterations in GABAergic system. Chronic blockade of CB2R
by AM630 increased GABA-Aα2 and GABA-Aγ2 gene expressions
in the cortex and amygdala. In contrast, the protein expression
of these genes was reduced by chronic treatment with AM630 in
the brain regions mentioned. Interestingly, activation of CB2R by
JWH133 reduced the GABA-Aα2 and GABA-Aγ2 gene expression
and increased its protein expression in the cortex and amygdala.
The opposite behavioral and molecular changes observed between
chronic CB2R blockade (AM630) or activation (JWH133) gives
support to the key role of these targets (CB2R, GABA-Aα2, and
GABA-Aγ2) in the behavioral effects of AM630 or JWH133. These
results provide new insights into the different molecular events
related to GABA-A receptor gene and protein expression pro-
duced by chronic manipulation of CB2R with CB2R agonism or
antagonism.
In summary, the data presented here provide evidence for the
interesting putative role of CB2R in anxiety and depressive-like
disorders and as a possible target for the development of a novel
class of anxiolytic or antidepressant drug. In this respect, the
administration of AM630 clearly decreased the anxious state of
DBA/2 mice (García-Gutiérrez et al., 2011). Further pharmaco-
logical studies are necessary to explore the potential therapeutic
uses of cannabinoid CB2R in humans and the precise mechanisms
underlying these effects.
CB2Rs IN SCHIZOPHRENIA
Different evidences support the involvement of CB2R in schizo-
phrenia disorders. Clinical remission of schizophrenia has been
reported to be accompanied by signiﬁcant decreases in AEA and
CB2R mRNA levels in peripheral blood mononuclear cells (Giuf-
frida et al., 2004). In addition, a recent publication revealed
a close relation between diminished CB2R function (polymor-
phism Q63R) and increased susceptibility to schizophrenia in the
presence of other risk factors (Ishiguro et al., 2010b).
The use of genetically modiﬁed mice led to further investi-
gate the potential role of CB2R in schizophrenic-related disorders.
Similarly to the alterations observed in schizophrenic patients
(Braff et al., 2001; Iyer et al., 2008; Peralta et al., 2010), the lack
of CB2Rs resulted in alterations of motor activity, anxiety and
depressive disorders, and cognitive deﬁcits including impaired
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sensoriomotor gating (Ortega-Alvaro et al., 2011). CB2KO mice
exhibited decreased spontaneous motor activity and increased
sensitivity to the motor stimulant effects of acute cocaine adminis-
tration in the open ﬁeld test. Indeed, as mentioned before, CB2KO
mice presented increased vulnerability to anxiogenic (light–
dark box and elevated plus-maze) and depressogenic-like stimuli
(TST). Furthermore, CB2KO mice showed disrupted short- and
long-term memory consolidation in the step down inhibitory
avoidance paradigm. Indeed, CB2KO mice presented a signiﬁ-
cantly reduced pre-pulse inhibition of the acoustic startle response
(PPI), alteration observed in rodent models of schizophrenia and
schizophrenic patients (Braff et al., 2001). Interestingly, the PPI
deﬁcit observed in CB2KO mice was markedly enhanced after
chronic oral treatment with risperidone, an antipsychotic drug
(see Table 3 for details).
It is known that schizophrenia is associated with brain abnor-
malities induced during the development of the CNS (Rapoport
et al., 2005; Ross et al., 2006). A number of ﬁndings suggest
a pro-neurogenic role of CB2R in the control of fundamental
neural cell processes (Harkany et al., 2007; Galve-Roperh et al.,
2008; Katona and Freund, 2008). Therefore, it can be hypothe-
sized that the lack of CB2R might impair neural development,
thus inducing relevant alterations in several brain areas. In this
respect, CB2KO mice presented increased dopamine D2 receptor
(D2R) and adrenergic α2C receptor (α2CR) gene expression in
prefrontal cortex and locus coeruleus, and decreased serotonin-
ergic 5-HT2C (5-HT2CR) and 5-HT2A receptors (5-HT2AR)
gene expression in the dorsal raphe and the prefrontal cortex,
respectively. Interestingly, risperidone treatment to CB2KO mice
induced a reduction in the gene expression of D2R, 5-HT2CR,
and 5-HT2AR in the prefrontal cortex, and α2CR in the locus
coeruleus; but increased 5-HT2CR and 5-HT2AR gene expression
in the dorsal raphe. Despite additional targets may be involved in
the behavioral alterations observed in CB2KO mice, the fact that
the risperidone tended to “normalize” the molecular alterations
observed in these mice supports the involvement of dopaminer-
gic, serotoninergic, and adrenergic alterations in the PPI deﬁcit of
CB2KO mice (Ortega-Alvaro et al., 2011). These results suggest
that CB2R deletion was related to the observed schizophrenia-like
behaviors. Pharmacological manipulation of CB2R may be fur-
ther explored as a potential therapeutic target for the treatment of
schizophrenia-related disorders.
A DISTINCTIVE ROLE OF CANNABIDIOL (CBD) IN
NEUROPSYCHIATRIC DISORDERS
Cannabidiol (CBD) is the main non-psychotropic phytocannabi-
noid found in the C. sativa plant, constituting up to 40% of its
extract. Recent comprehensive reviews indicate that CBD is one
of the most promising candidates for therapeutic use in a wide
range of disorders, including neuropsychiatric (Mechoulam et al.,
2007; Zuardi, 2008; Izzo et al., 2009). As discussed bellow, part
of its effects seems to depend on facilitation of eCB-mediated
neurotransmission.
CBD IN ANXIETY AND DEPRESSION
Initial studies in laboratory animals produced contradictory
results.Whereas Zuardi and Karniol (1983) showed that low doses
(10mg/kg) of CBD attenuated conditioned emotional responses
in rats, Silveira Filho and Tuﬁk (1981) failed to ﬁnd any effect
of a much higher dose (100mg/kg) in a conﬂict paradigm.
These apparently opposite results were subsequently explained by
Guimarães et al. (1990), who veriﬁed that CBD causes an inverted
U-shaped dose-related anxiolytic response curve in the elevated
plus-maze,with the anxiolytic doses ranging from 2.5 to 20mg/kg.
Subsequent studies employing diverse animal models, including
the elevated plus-maze, Vogel conﬂict test, contextual fear condi-
tioning, marble burying test, and attenuation of stress responses,
conﬁrmed that systemically injected CBD decreases anxiety-like
behaviors in rodents (Onaivi et al., 1990; Guimarães et al., 1994;
Moreira et al., 2006; Resstel et al., 2006; Casarotto et al., 2010).
More recently the brain sites responsible of these effects have
been investigated by direct brain administration of CBD. The drug
caused anxiolytic-like effects after microinjection into the dorso-
lateral periaqueductal gray (dlPAG), bed nucleus of the stria ter-
minalis (BNST), and prelimbic medial prefrontal cortex (Campos
andGuimarães, 2008;Moreira et al., 2009;Alves et al., 2010; Lemos
et al., 2010; Soares et al., 2010; Gomes et al., 2011). It also facili-
tated extinction in a contextual aversive conditioning model after
intracerebral ventricular administration (Bitencourt et al., 2008).
Interestingly, in the infralimbic prefrontal cortex CBD induced
an anxiogenic effect, facilitating conditioned emotional responses
(Lemos et al., 2010). Moreover, no consistent effect was found in
the amygdala (Lisboa and Guimarães, unpublished results). Taken
together, these results indicate that the anxiolytic effects of CBD
depend on drug action in speciﬁc brain areas related to defensive
responses.
Clinical studies have conﬁrmed that CBD possess anxiolytic
properties. In addition to prevent the anxiogenic effects of high
doses of THC (Zuardi et al., 1982), CBD was able to decrease
anxiety in healthy subjects submitted to a simulated public speak-
ing paradigm (Zuardi et al., 1993a). Using a similar paradigm,
Bergamaschi et al. (2011) have recently shown that the drug
reduces public speaking anxiety in treatment-naïve social phobic
patients. In agreement with these ﬁndings, neuroimaging stud-
ies show that CBD can change brain activity in regions related
to emotional responses. It impairs connectivity between the pre-
frontal and subcortical regions (Fusar-Poli et al., 2010), attenuates
blood oxygenation level-dependent responses to fearful faces in
the amygdala and cingulate cortex (Fusar-Poli et al., 2009) and
decreases activation in the left amygdala–hippocampal complex
and left posterior cingulate gyrus (Crippa et al., 2004). In rela-
tion to depressive-related disorders, CBD has been reported to
prevent the physiological and delayed anxiogenic consequences of
restraint stress in animal models (Resstel et al., 2009), an effect that
has been related to depressive responses (Guimarães et al., 1993).
More recently, CBD was shown, similarly to the prototype anti-
depressant imipramine, to decrease immobility time in the forced
swimming test (Zanelati et al., 2010). Although more studies are
clearly needed, these initial results suggest that CBD does possess
antidepressive properties.
CBD AND PSYCHOSIS/SCHIZOPHRENIA
Several studies performed in laboratory animals during the 1970s
indicated that CBD could interact with the main cannabinoid
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present in theC. sativa plant, delta-9-tetrahydrocannabinol (THC,
for review see Zuardi et al., 2006a; Zuardi, 2008). In a seminal
study published in 1982, Zuardi et al. (1982) observed that CBD
could block the psychotomimetic and anxiogenic effects of THC
in healthy volunteers. This observation led to the hypothesis that
CBD could have antipsychotic and/or anxiolytic properties. The
former proposal was supported by preclinical results indicating
that the drug is able to reduce the stereotypies and hyperloco-
motion caused by apomorphine and amphetamine, respectively,
without causing catalepsy or increasing prolactin levels (Zuardi
et al., 1991, 1993b; Moreira and Guimarães, 2005). This “atypi-
cal” antipsychotic proﬁle was further conﬁrmed in a c-Fos study
where CBD, similarly to clozapine, increased c-Fos expression in
limbic areas and prefrontal cortex, but not in the dorsal striatum
(Guimarães et al., 2004).
In addition to dopamine-based models predictive of antipsy-
chotic activity, CBD effects have also been tested in glutamate-
based models. CBD blocked the hyperlocomotion induced by
ketamine (Moreira and Guimarães, 2005) as well as the disrup-
tion of pre-pulse inhibition induced by MK-801 (Long et al.,
2006). CBDwas also able to restore the deﬁcit in social interactions
induced by this drug (Gururajan et al., 2011).
The possible antipsychotic proﬁle of CBD indicated by these
preclinical results is further supported by clinical studies (for
review see Zuardi, 2008). In agreement with the initial report by
Zuardi et al. (1982), showing that CBD is able to antagonize the
psychotomimetic effects of THC in healthy volunteers, the pres-
ence of this compound in Cannabis strains seems to be protective
against the occurrence of psychotic reactions (Morgan and Cur-
ran, 2008) as well as Cannabis-associated decrease in hippocampal
volume (Demirakca et al., 2011). CBD is also able to attenuate
psychosis symptoms induced by ketamine or l-DOPA in healthy
volunteers and Parkinson’s patients, respectively (Zuardi et al.,
2009). In accordance with these results, preliminary studies in
schizophrenic patients showed positive therapeutic effects of CBD
(Zuardi et al., 1995, 2006b).
CBD MECHANISMS AND THE eCB SYSTEM
Results of experiments aimed at elucidating CBD mechanisms are
usually complicated by the common bell-shaped dose–response
curves produced by this drug (Campos and Guimarães, 2008; Izzo
et al., 2009). Even so, it is now clear that multiple pharmacological
actions are involved in the wide range biological effects induced by
CBD(Izzo et al., 2009). These actions include complex interactions
with the eCB system. CBD was initially described as possessing lit-
tle afﬁnity for cannabinoid receptors (Petitet et al., 1998; Thomas
et al., 1998). A more recent study, nonetheless, has suggested that
CBD can antagonize CB1Rs and CB2Rs at relatively low concen-
trations (Thomas et al., 2007). This antagonism, however, seems
to be non-competitive in nature, with evidence suggesting that
CBD could act as a CB1R or CB2R inverse agonist (Pertwee,
2008). Contrasting with these ﬁndings, CBD could also facilitate
eCB-mediated neurotransmission by decreasing AEA hydrolysis
or reuptake (Bisogno et al., 2001).
The ﬁndings regarding eCBs involvement in CBD effects, how-
ever, have been mainly obtained in studies performed in vitro and
little is known about the involvement of these mechanisms in the
central effects of the drug. To investigate this issue, we initially
tested if facilitation of eCB-mediated neurotransmission could
explain the anxiolytic effects of CBD in the dlPAG. This hypothe-
sis was based on our previous study showing that direct injection
of AEA into this region induces anxiolytic-like effects that were
prevented by prior administration of AM251, a CB1R antago-
nist (Moreira et al., 2007). Surprisingly, the same dose of AM251
that had antagonized AEA failed to prevent CBD anxiolytic effects
in the dlPAG (Campos and Guimarães, 2008). Considering that
CBD could also act, at μM concentration range, as an agonist of
5-HT1ARs in vitro (Russo et al., 2005) and in vivo (Mishima et al.,
2005), we decided to test if CBD effects would be prevented by
local pre-treatment with WAY100635, a selective 5-HT1AR antag-
onist. Supporting this hypothesis, this drug completely blocked the
anxiolytic effects of CBD (Campos and Guimarães, 2008). Follow-
ing this initial result, we have now conﬁrmed that WAY100635 is
able to prevent CBD anxiolytic effects after intracerebral injec-
tions into the BNST (Gomes et al., 2011) or dlPAG (Soares et al.,
2010) as well as following CBD systemic administration (Ress-
tel et al., 2009). 5-HT1A mechanisms are also responsible for the
antidepressive-like effects of CBD in the forced swimming test
(Zanelati et al., 2010). Despite these ﬁndings, which clearly related
5-HT1A-mediated neurotransmission with CBD anxiolytic and
antidepressive effects, more recent results showed that the eCB
system is also involved in at least some of the central effects of
CBD. For example, the facilitatory effect of intracerebroventricu-
lar (i.c.v.) administration of CBD in contextual fear-conditioning
extinction was prevented by Rimonabant (Bitencourt et al., 2008).
Also, the plastic effects of repeated CBD administration seem to
involve eCB mechanisms. For example, chronic CBD treatment
was shown to increase adult neurogenesis in the dentate gyrus,
an effect that was absent in CB1KO mice (Wolf et al., 2010). In
line with these results, the in vitro proliferative effects of CBD
on embryonic hippocampal cells were prevented by CB1 or CB2
receptor antagonists (Campos et al., 2010).
We have also recently found that a CB1R antagonist, but not a
5-HT1AR, is able to prevent the effects of CBD in the marble bury-
ing test (Casarotto et al., 2010). Although initially proposed as an
animal model aimed at detecting possible anxiolytic drug effects,
it is now thought to evaluate a natural, repetitive behavior that
can become compulsive. This test, therefore, has been proposed to
model aspects of obsessive–compulsive disorder (OCD; Thomas
et al., 2009). CBD effects in this model, depending on CB1R rather
than on 5-HT1AR, gives support to the interpretation that the
marble burying test (and OCD) engages brain mechanisms some-
how different from those of related to classical animal models of
anxiety (Witkin, 2008).
Both CBD and AEA can activate TRPV1Rs (Bisogno et al.,
2001). These receptors are expressed in several brain areas related
to anxiety such as the amygdala, hippocampus, prefrontal cortex,
and PAG (Cristino et al., 2006). Activation of TRPV1 receptors
can facilitate glutamate release (Marsch et al., 2007; Xing and Li,
2007), the main excitatory neurotransmitter in the CNS. Since
antagonism of glutamate and TRPV1Rs in the dlPAG induce
anxiolytic-like effects (Aguiar and Guimarães, 2009; Terzian et al.,
2009), we hypothesized that at higher doses CBD could also
be activating local TRPV1Rs (directly and maybe by inhibiting
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AEA metabolism/uptake), facilitating glutamate neurotransmis-
sion and increasing anxiety. Corroborating this proposal,we found
that a low dose of capsazepine, a TRPV1R antagonist, was able to
turn the higher but ineffective dose of CBD into an anxiolytic
one (Campos and Guimarães, 2009). Interaction with TRPV1Rs
has also been suggested to explain the antipsychotic-like effects of
CBD on MK-801 induced disruption of PPI (Long et al., 2006).
Other mechanisms have also been proposed to account for the
effects of CBD, for example blockade of adenosine uptake (Carrier
et al., 2006) and antagonism of the putative cannabinoid recep-
tor GPR55 (Mechoulam et al., 2007). Although the former has
been related to CBD anxiolytic properties in a preliminary study
(Carrier et al., 2007), the involvement of these mechanisms in the
central effects of this drug remains to be further investigated. In
summary, preclinical and clinical studies indicate that CBD has
therapeutic potential in several neuropsychiatric disorders that
depend on multiple mechanisms, including interaction with the
eCB system. In addition, considering its safety proﬁle (Mechoulam
et al., 2007; Zuardi, 2008; Izzo et al., 2009), CBD could be a useful
pharmacological tool to modulate this system.
THE eCB SYSTEM AND EATING DISORDERS: TOWARD A
NEW THERAPEUTICALLY VALID APPROACH?
PATHOPHYSIOLOGY OF EATING DISORDERS
Food intake or eating is the process by which edible substances
are consumed in order to balance the energy expenditure in living
creatures. This process relies in physiologicmechanisms regulating
appetite and the natural drive to eat. In some conditions human
feeding behavior is altered leading to diseases, collectively known
as eating disorders. These are a group of disorders characterized by
physiological and psychological disturbances in appetite or food
intake. They can be divided into three main pathologies, i.e., binge
eating, bulimia nervosa (BN), and anorexia nervosa (AN). Binge-
eating disorder is associated with three or more of the following:
eating until feeling uncomfortably full; eating large amounts of
food when not physically hungry; eating much more rapidly than
normal; eating alone due to embarrassment; feeling of disgust,
depression, or guilt after overeating. Criteria includes occurrence
on average, at least 2 days a week for 6months. Binge eating is
not associated with compensatory behavior (i.e., purging, exces-
sive exercise, etc.) and does not co-occur exclusively with BN or
AN (From DSM-IV, 1994). BN is characterized by a cycle of binge-
eating followed by purging to avert weight gain. Purging methods
often include self-induced vomiting, use of laxatives or diuretics,
excessive exercise, and fasting. AN is characterized by the loss of
appetite and is associatedwithother features including an excessive
fear of becoming overweight, body image disturbances, signiﬁcant
weight loss, refusal to maintain minimal normal weight, excessive
exercise, and amenorrhea (Walker, 1994). In this reviewwewill not
include obesity because actually it is not formally considered an
eating disorder. However, we would like to underline the increas-
ing evidence dealing with speciﬁc changes in the CNS of obese
people, including those occurring in brain areas involved in the
rewarding aspects of food (reviewed in (Volkow and Wise, 2005).
Likewise, and maybe reﬂecting direct central consequences of
obesity, it is noteworthy the high incidence of anxiety and depres-
sion (also present in classical eating disorders) in obese people,
affecting around 50% of this population. Also deserving greater
consideration are the striking similarities in the pathophysiologic
sequel occurring with obesity and addiction, also suggesting a re-
evaluation of how these diseases are classiﬁed (Volkow and Wise,
2005).
Eating disorders can be chronic and disabling conditions char-
acterized by aberrant patterns of feeding behavior and weight
regulation, including abnormal attitudes and perceptions toward
body weight and shape (Kaye, 2008). Indeed, AN has the high-
est mortality rate among neuropsychiatric diseases (Lowe et al.,
2001). The etiologies of these diseases are at present poorly under-
stood, but both AN and BN occur most frequently in adolescent
females. This increased incidence and prevalence may very well
be a direct reﬂection of cultural pressures for thinness (Strober
et al., 1995). However, the discrete occurrence and heritability
suggest there are some biological vulnerabilities involved in these
diseases (Kaye, 2008). In fact, twin studies on AN and BN suggest
there is a 50–80% genetic contribution to these diseases (Bulik
et al., 1998; Klump et al., 2001). However, there is little knowl-
edge about the connection between psychological symptoms and
the neuropathophysiology associated with these diseases and on
how such genetic vulnerabilities impact on brain pathways and
what systems are primarily involved. Because of the neuropsy-
chiatric nature of these diseases, the monoamine systems (i.e.,
serotonin, dopamine, and norepinephrine pathways) have been
explored in greater detail. Among these, the serotoninergic sys-
tem may be the more adversely affected and its deregulation is
present in AN patients. However, the response to selective sero-
tonin reuptake inhibitors is variable among patients suffering
different subtypes of the illness, and the efﬁcacy of such med-
ication has been also questioned due to the common occurrence
of relapse (Kaye et al., 2001; Walsh et al., 2006). Current research
on eating disorders also points to a deregulation of neuronal cir-
cuits involved in food intake, including those related to emotional
and reward pathways linked to feeding behavior (Stoving et al.,
2009). In particular, a deranged leptin signaling system has been
found in AN and BN (Monteleone et al., 2004; Holtkamp et al.,
2006) and it has been hypothesized that the reward systems could
be compromised leading to food intake-related dysphoria that
would promote a vicious cycle of decreasing eating in order to
avoid the dysphoric consequences of food consumption (Kaye,
2008). In this context, the reward system could have an important
role since it integrates “liking” (pleasure/palatability) and “want-
ing” (appetite/incentive motivation) perceptions associated with
food and, thus, AN and BN could be considered as dependency
syndromes.
THE ROLE OF THE eCB SYSTEM IN ENERGY HOMEOSTASIS
The eCB system is strategically located in all the key points involved
in food intake and energy expenditure, both at the central and the
peripheral level. Thus, it is perhaps one of the few that can coordi-
nate all the players involved in energy balance (reviewed in Pagotto
et al., 2006; Matias and Di Marzo, 2007). Together with its action
on peripheral tissues, the eCB system inﬂuences feeding behavior
at the CNS by acting on circuits located in the hypothalamus, the
reward system and the brain stem, with the overall net effect being
anabolic (reviewed in Di Marzo et al., 2009).
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Brieﬂy, the hypothalamus is a key brain structure involved in
energy balance homeostasis. Despite the low expression of CB1R
in the hypothalamus, a number of studies demonstrate that eCBs
through CB1Rs exerts a profound inﬂuence on the hypothalamic
regulationof food intake (reviewed inBermudez-Silva et al., 2011).
CB1Rs are also important in the hypothalamic leptin-mediated
anorectic effects (Di Marzo et al., 2001). Leptin inhibits eCB pro-
duction in the hypothalamus and, conversely, hypothalamic eCBs
are increased in genetically obese rodents lacking leptin or its
receptor (Di Marzo et al., 2001). The reward system is a group
of brain structures which regulate and control behavior by induc-
ing pleasurable effects. The major rewarding pathway in the brain
is the mesolimbic pathway that goes from the ventral tegmental
area via the medial forebrain bundle to nucleus accumbens, which
is the primary release site for the main brain’s pleasure chemical,
i.e., the neurotransmitter dopamine.CB1Rs are expressed in presy-
naptic glutamatergic andGABAergic nerve terminals in the ventral
tegmental area, and eCBs are synthesized by ventral tegmental area
dopamine neurons, having a role in the ﬁne-tuned regulation of
these cells (Maldonado et al., 2006). While it is still unclear exactly
what cell populations express CB1Rs in the nucleus accumbens, it
seems that eCBs within this area are able of increasing food intake
in a CB1-dependent manner (Kirkham et al., 2002). Additional
studies have also reported that eCBs acting in the nucleus accum-
bens modulate the palatability of food (Mahler et al., 2007). The
brainstem is also a relevant player in food intake regulation: sati-
ety signals from the stomach and duodenum reach the brainstem
through sensory and vagal ﬁbers. Among these, cholecystokinin
(CCK) and peptide YY have been related with the eCB system
(reviewed in Di Marzo et al., 2009; Bermudez-Silva et al., 2010).
CB1Rs are expressed in the brainstem and in vagal afferent neu-
rons modulating these signals (Burdyga et al., 2004;DiPatrizio and
Simansky, 2008). Furthermore, eCB tone changes in the brainstem
during the different phases of eating (reviewed in Di Marzo et al.,
2009).
THE eCB SYSTEM IN EATING DISORDERS
Thewidespread role of the eCB system in regulating energybalance
has spawned investigations into putative defects in eCB signaling
that may underlie eating disorders. Increased blood levels of AEA
have been found in both AN and binge-eating disorder patients,
but not in BN patients (Monteleone et al., 2005). Indeed, AEA
levels were signiﬁcantly and inversely correlated with plasma lep-
tin concentrations in both healthy controls and anorexic women.
Interestingly, there is evidence to suggest that hypoleptinemia in
AN patients may be an important factor underlying the excessive
physical activity (Holtkamp et al., 2006), one of the hallmarks in
AN. Thus, these results suggest that alterations in the eCB system
associated with deregulated leptin signaling could be involved in
the pathophysiology of AN. It is well-known that the eCB system
and leptin interact functionally at the molecular level (reviewed in
Bermudez-Silva et al., 2011), and thus it is easy to draw a theoreti-
cal frame in support of the important role played by both systems
in AN and the therapeutic potential of leptin and cannabinoids
in this disease (Stoving et al., 2009). Furthermore, elevated lev-
els of CB1R but not CB2R mRNA have been found in the blood
of females with AN and BN, further supporting the hypothesis
of deregulated eCB signaling in eating disorders (Frieling et al.,
2009). Paradoxically, these authors found an association between
lower CB1R expression and more severe forms of the disorders.
AEA belongs to the lipid family of acylethanolamides. Another
member of this group of lipids, named oleoylethanolamide, has
also an important role on energy balance by promoting satiety and
lipolysis through the activation of the PPARα (Fu et al., 2003). This
molecule has an anorexigenic action by inducing oxytocin expres-
sion in the paraventricular nucleus of the hypothalamus and, inter-
estingly, preliminary clinical results have shown altered levels of
oleoylethanolamide in the cerebrospinal ﬂuid and plasma of sub-
jects recovered from eating disorders (Gaetani et al., 2008). These
preliminary observations could extend the ﬁndings of altered lev-
els of eCBs in eating disorders to a more general involvement of
acylethanolamides.
Given the important contribution of genetics to AN and BN
(in fact, the heritability estimates are similar to disorders typi-
cally viewed as biological like schizophrenia and bipolar disorder)
human genetic association studies have been performed in order
to identify genes involved in these pathologies, including genes
belonging to the eCB system. Among these, CNR1 and CNR2
(the genes encoding cannabinoid CB1Rs and CB2Rs, respectively),
as well as the genes encoding the main enzyme responsible in
the degradation of AEA (FAAH), NAAA (N -Acylethanolamine-
hydrolyzing acid amidase, which functions similar to FAAH but
has adifferent optimal pH),andMAGLhavebeen studied.Theﬁrst
family based study involved 52 families (parents with one or two
affected siblings) that were genotyped for the (AAT) trinucleotide
repeat of CNR1 gene. The distribution of alleles transmitted to the
patients was not found to be signiﬁcantly different from the non-
transmitted parental alleles. However, upon dividing the samples
to restricting and binging/purging subtypes of AN, the data analy-
sis revealed a preferential transmission of different alleles in each
of the subtypes, suggesting restricting AN and binging/purging
AN may be associated with different alleles of the CNR1 gene
(Siegfried et al., 2004). However, a subsequent study involving
up to 91 German AN trios (patient with AN and both biologi-
cal parents) was unable to conﬁrm these results, nor did it show
an association for any of 15 single nucleotide polymorphisms
representative of regions with restricted haplotype diversity in
FAAH, NAAA, and MAGL genes (Muller et al., 2008). Another
study in 115 overweight/obese subjects with binge-eating disor-
der, 74 non-binge-eating disorder patients with obesity and 110
normal weight healthy controls investigated one of these FAAH
polymorphisms, previously implicated in obesity in binge-eating
disorder, and reporting a lack of association (Monteleone et al.,
2008) and in a more recent article these authors studied the
association of this FAAH polymorphism and the CNR1 poly-
morphism in both AN and BN, in 134 patients with AN, 180
patients with BN and 148 normal weight healthy controls (Mon-
teleone et al., 2009). The authors found a signiﬁcant increase in
the frequency of both polymorphisms in AN and BN patients,
a result in sharp contrast with the previous ﬁndings by Muller
et al. (2008) that showed a lack of association of these polymor-
phisms with AN. Additionally, Monteleone et al. (2009) found
a synergistic effect of the two polymorphisms in AN but not
in BN. Finally, a recent article has detected an association of
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a CNR2 polymorphism with both AN and BN (Ishiguro et al.,
2010a) in a study comprising in 204 subjects with eating disor-
ders and 1876 healthy volunteers in Japanese population. Taken
together, the human genetic association studies show evidence
of association between eCB system genes and eating disorders,
but further studies are necessary to deﬁnitively conﬁrm these
ﬁndings.
THERAPEUTIC USE OF CANNABINOID DRUGS IN EATING DISORDERS
Cannabis preparations have been used for both medicinal and
recreational purposes for centuries. Its ancient medicinal use has
been primarily related to ameliorate pain and increase appetite in
disease states. However, because of their psychostimulant prop-
erties and the lack of an adequate body of knowledge, their use
in western medicine has been excluded until recently. During
the last 20 years this picture has dramatically changed. There has
been an exponential increase in the knowledge of the molecular
mechanisms underlying cannabinoid effects, and morphological,
physiological and pathophysiological studies have shown that the
molecular system supporting these effects (i.e., the eCB system),
is ubiquitous and has a highly relevant role in maintaining whole
body homeostasis and, especially, energy homeostasis (Matias and
Di Marzo, 2007). This fact has led to an increased interest in
the medical use of cannabinoid-related drugs. Thus, in 1985 the
Food and Drug Administration approved Marinol® (dronabinol),
a synthetically derived THC preparation, to relieve nausea, and
vomiting associated with chemotherapy in cancer patients who
have failed to respond adequately to other antiemetics, and in 1992
this compound was also approved for inducing appetite in AIDS
patients suffering from cachexia (Nelson et al., 1994; Beal et al.,
1995). Similarly, Nabilone® (a synthetic cannabinoid that mimics
THC) was also approved in 1985 for ameliorating the nausea of
cancer chemotherapy. A more controversial step forward was the
use of a cannabinoid CB1R antagonist/inverse agonist (rimona-
bant) for management of complicated obesity. Although the Food
and Drug Administration never approved this drug, the European
Medicine Agency did and Acomplia® (the commercial name of
rimonabant) was in the market for approximately 2 years. Despite
the weight loss and improved cardiometabolic proﬁle observed
in obese patients, the drug had to be removed from the market
due to its undesirable central side effects (see previous sections,
but also Bermudez-Silva et al., 2010 for review). More recently,
Sativex® (the combination of THC and CBD) has been marketed
in Canada and European countries like the United Kingdom and
Spain for the treatment of spasticity due to multiple sclerosis, and
it is currently in phase III clinical development for the treatment
of cancer pain.
Taken into account the good therapeutic management of
cannabinoids in cachexia and malnutrition associated with can-
cer and AIDS, it looks feasible that this kind of pharmacotherapy
could be also useful in the treatment of eating disorders. Unfor-
tunately, there are only two small trials assessing cannabinoid
treatment in AN (reviewed in Stoving et al., 2009). The former
involved 11 AN patients in a 4-week crossover trial and THC
treatment resulted in increased sleep disturbances and interper-
sonal sensitivity, whereas there was no signiﬁcant effect on weight
gain (Gross et al., 1983). Unfortunately, this study raised several
concerns given it was an in-patient study and the occasional tube
feeding was used. In addition, THC was compared to diazepam
instead of placebo, which could be a confounding factor given
diazepam has also been reported to increase food intake per se
(Naruse et al., 1991). The latter involved nine AN out-patients
treated with THC. The results showed a signiﬁcant improvement
of depression and perfectionism scores without improving weight
gain (Berry, 2006).
Currently, there is an ongoing phase III clinical trial involv-
ing 22 subjects to reveal if severe chronic AN patients treated with
Marinol® have signiﬁcant improvement onweight,with secondary
objectives of the study being evaluation of eating disorder inven-
tory scale,motor and inner restlessness and endocrine parameters3
(EudraCTNumber: 2007-005631-29).With this very limitednum-
ber of performed trials (the last one being still not ﬁnished) it
seems clear that no conclusions can be drawn out regarding the
therapeutic validity of a cannabinoid-based approach in eating
disorders. However, the satisfactory clinical use of cannabinoid
agonists in other pathologies demands and encourages the devel-
opment of further clinical trials on eating disorders patients.
Interestingly, a very recent preclinical study in rodent have shown
that themain active constituent of cannabis,THC, is able of reduc-
ing the weight loss associated with the development of AN via a
mechanism involving reduced energy expenditure (Verty et al.,
2011), thus providing encouraging preclinical data on the validity
of a eCB-based therapy in AN.
CONCLUDING REMARKS
Evidence for a critical role of the eCB system in neuropsychiatric
disorders has been provided, and special attention has been paid
to its contribution to the emotional and cognitive deﬁcits com-
promised in these disorders. Not only CB1Rs, but also CB2Rs and
CBD, through facilitation of eCB-mediated neurotransmission,
have been involved in the emotional and cognitive deﬁcits reported
in anxiety disorders, depression, and schizophrenia. Indeed, a
deregulation of the eCB system seems to be in the bases of several
neuropsychiatric disorders, including eating disorders. The phar-
macological enhancement of eCB signaling has yield promising
results in rodents, particularly as an anxiolytic and antidepres-
sant therapy. Eating disorders may also beneﬁt of this therapeutic
approach, and a clinical trial with synthetic THC is ongoing for
the management of severe AN. However, in spite of these poten-
tial beneﬁts, further research is needed to prevent undesirable side
effects. In fact, the prolonged and continuous activation of the eCB
system,e.g., by chronic cannabis consumption,has been associated
with an increased risk for schizophrenia. Alternatively, CBD may
arise as an optimal candidate to modulate the eCB system. CBD
has consistently demonstrated an anti-anxiety and antidepressant
proﬁle, and its potential as an antipsychotic drug is gaining rel-
evance in preclinical and clinical studies. In conclusion, the eCB
system is seriously involved in neuropsychiatric disorders. In spite
of the promising results achieved in animal studies, detrimental
consequences of manipulating this endogenous system cannot be
underestimated over the potential and promising perspectives of
its therapeutic manipulation.
3https://www.clinicaltrials register.eu
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